GlassScriptPhysician profile
Richard John Begg
NPI 1376549741
$17,164.45
in general payments reported to CMS, 2019-2025
43 companies · $1,692 in 2025
The $1,692 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,426 · 2020: $1,065 · 2021: $1,510 · 2022: $2,369 · 2023: $2,865 · 2024: $2,237 · 2025: $1,692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,794.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,794.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,737.91 | 2019-2025 | Watchman Access System, Watchman, Watchman Flx |
| Edwards Lifesciences Corporation | $2,076.79 | 2019-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Heartflow, INC. | $1,819.49 | 2021-2025 | Ffrct |
| Novartis Pharmaceuticals Corporation | $1,270.60 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,165.20 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $997.14 | 2019-2025 | Lifevest |
| Abbott Laboratories | $852.05 | 2019-2025 | Aveir, Gallant, Cardiomems |
| Shockwave Medical, INC | $707.26 | 2022-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Astrazeneca Pharmaceuticals LP | $617.74 | 2019-2025 | Farxiga, Andexxa, Lokelma |
| Pfizer INC. | $596.42 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $569.26 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $446.41 | 2019-2025 | Repatha, Repatha |
| Abiomed | $411.14 | 2019-2025 | Impella |
| Atricure, INC. | $320.11 | 2020-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $186.48 | 2021-2025 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.65 | 2021-2025 | Jardiance |
| Novo Nordisk INC | $173.37 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Getinge USA Sales, LLC | $133.50 | 2019-2021 | |
| Scpharmaceuticals INC. | $90.45 | 2023-2025 | |
| Actelion Pharmaceuticals US, INC. | $89.86 | 2019-2024 | Opsumit |
| W. L. Gore & Associates, INC. | $67.51 | 2023 | Excluder Conformable Aaa Endoprosthesis With Active Control |
| Daiichi Sankyo INC. | $65.89 | 2019-2023 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $52.76 | 2019-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $49.29 | 2023 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $46.65 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $44.42 | 2023-2025 | Verquvo |
| Stryker Corporation | $44.36 | 2025 | Flowtriever |
| Inspire Medical Systems, INC. | $43.96 | 2024 | Inspire |
| Kiniksa Pharmaceuticals International, Plc | $36.96 | 2024 | Arcalyst |
| Esperion Therapeutics, INC. | $35.94 | 2021-2025 | Nexletol |
| Cvrx, INC. | $29.02 | 2021-2024 | Barostim Neo System |
| Medtronic, INC. | $27.65 | 2023 | Corevalve Evolut R |
| Lundbeck LLC | $25.99 | 2020-2021 | |
| Kestra Medical Technology Services, INC. | $20.84 | 2023 | Assure Wcd |
| United Therapeutics Corporation | $20.41 | 2025 | Tyvaso |
| Livanova USA, INC. | $15.97 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $15.13 | 2023 | Inpefa |
| Amarin Pharma, INC. | $14.97 | 2022 | |
| Tactile Systems Technology INC | $14.84 | 2024 | Entre Plus, Flexitouch Plus |
| Impulse Dynamics (USA) INC. | $13.24 | 2024 | Optimizer |
| Kowa Pharmaceuticals America, INC. | $12.44 | 2020 | |
| Gilead Sciences, INC. | $12.04 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $11.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Begg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.